Silo pharma extends agreement for experimental rheumatoid arthritis nanoparticle homing peptide

Englewood cliffs nj, july 07, 2021 (globe newswire) -- silo pharma, inc. (otc qb: silo), a developmental stage biopharmaceutical company, today announced that it has extended its exclusive option agreement with the university of maryland, baltimore to explore a novel invention generally known as “joint-homing peptides for use in the investigation and treatment of arthritogenic processes.”
SILO Ratings Summary
SILO Quant Ranking